Quarterly ResultAug 12, 2026, 04:15 PM
Sera Prognostics Q2 Revenue $30K; Net Loss $9.1M
AI Summary
Sera Prognostics reported Q2 2026 revenue of $30,000, an increase from $17,000 in the prior year, while net loss widened to $9.1 million from $8.0 million. The company highlighted significant operational progress, including the launch of a fourth partnership program and Illinois Medicaid mandating coverage for its PreTRM® Test. Clinical data from the PRIME study showed the PreTRM® Test reduced NICU admissions by 22% among first-time mothers, and the company maintains a strong balance sheet with $80.3 million in cash, expected to fund operations through 2029.
Key Highlights
- Q2 2026 revenue was $30,000, up from $17,000 in Q2 2025.
- Q2 2026 net loss was $9.1 million, compared to $8.0 million in Q2 2025.
- Q2 2026 net loss per share was $(0.18), compared to $(0.16) in Q2 2025.
- Ended quarter with $80.3 million in cash, funding operations through 2029.
- Illinois Medicaid mandated coverage for PreTRM® Test for ~50,000 births.
- PreTRM® Test-guided care reduced NICU admissions by 22% in first-time mothers.
- Launched fourth partnership program for PreTRM® Test adoption.
- European CE marking submission for PreTRM® Test expected in Q4 2026.
Price Impact
More from SERA